Introduction
Chronic lymphocytic leukemia (CLL) is the most common human hematologic malignancy and, despite substantial scientific efforts, remains an incurable disease. Whereas some patients with CLL have a slow course of disease, most face inevitable progression and have fatal outcomes. 1, 2 CLL is characterized by the accumulation of largely nonproliferating leukemic B cells that are resistant to apoptosis. 3 An increasing body of evidence suggests that the apoptotic block of CLL B cells is linked to constitutively activated signaling pathways, including an active NFB pathway. 4, 5 In fact, CLL B cells exhibit high constitutive levels of NFB activity compared with nonmalignant human B cells. 5 Because NFB regulates the expression of antiapoptotic molecules including Bcl-2 and XIAP, a sustained activation of NFB pathway is critical for the survival of CLL B cells. 6 Thus, identification of the altered pathways regulating NFB activity in CLL B cells may lead to the discovery of novel therapeutic targets to antagonize NFB activation and induce apoptosis in these leukemic B cells.
Glycogen synthase kinase (GSK)-3, a serine/threonine protein kinase, was first described as a component of the metabolic pathway for glycogen synthase regulation. 7 Two homologous mammalian GSK-3 isoforms are encoded by different genes, GSK-3␣ and GSK-3␤. 8 It has been shown that, similar to the disruption of the NFB p65 or IB kinase ␤ (IKK␤) genes, ablation of the murine GSK-3␤ gene is lethal to embryos as a result of TNF␣-induced hepatocyte apoptosis and massive liver degeneration. [9] [10] [11] These findings suggest a role for GSK-3␤ (but not GSK-3␣) in the regulation of NFB activation. The early steps leading to NFB activation after tumor necrosis factor ␣ (TNF␣) treatment (degradation of IB␣ and translocation of NFB to the nucleus) were unaffected in GSK-3␤-deficient mouse embryonic fibroblasts (MEFs), indicating that NFB is regulated by GSK-3␤ at the level of the transcriptional complex. 11 Consistent with this idea, we have recently shown that GSK-3␤ participates in NFB-mediated pancreatic cancer cell survival and proliferation by regulating NFB activity at a point downstream of the activation of the IKK complex. 12 Taken together, these data rule out an effect of GSK-3␤ on the cascade of proteins that culminates in phosphorylation of IB␣ and its degradation and suggest that GSK-3␤ may regulate the nuclear activity of NFB p65/p50.
Although CLL B cells exhibit high constitutive levels of NFB activity, 5 the localization of GSK-3␤ in human CLL B cells and whether GSK-3␤ affects NFB activity are unknown. In the present study, we find that GSK-3␤ accumulates in the nuclei of human CLL B cells. We demonstrate that pharmacologic inhibition of GSK-3 leads to depletion of its nuclear pool, suppression of NFB transcriptional activity, decreased expression of antiapoptotic proteins (XIAP, Bcl-2), and enhanced apoptosis in CLL B cells. From a mechanistic perspective, we provide evidence that inhibition of GSK-3␤ affects histone modification at two NFB target genes (XIAP, Bcl-2), resulting in its transcriptional repression and decreased survival of human CLL B cells.
Patients, materials, and methods

Patient selection and purification of lymphocytes
Blood was obtained from healthy donors or patients with CLL who had provided written informed consent. The Mayo Clinic Institutional Review Board, in accordance with the Declaration of Helsinki, approved the laboratory study. All patients with CLL had a confirmed diagnosis using the National Cancer Institute working group 1996 definition. 13 Patients in this cohort were from all Rai stages and had not been treated for at least 6 weeks before blood processing for this study. Peripheral blood mononuclear cells (PBMC) were separated from heparinized venous blood by density gradient centrifugation. To remove adherent cells, PBMC were suspended in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and incubated in plastic dishes at 37°C for 1 hour before collection of nonadherent cells. To obtain at least 95% purity of CLL B cells, nonadherent cells were depleted of T cells by incubation with sheep erythrocytes. For some experiments, we purified CLL B cells from magnetic bead columns. In brief, highly purified CD19 ϩ B cells ( Ͼ 95%) were obtained from PBMC by standard negative selection using a cocktail of subset-specific antibodies conjugated with magnetic beads (Miltenyi Biotech, Auburn, CA). These purified CLL B cells were then either used immediately for the laboratory studies described below or cryopreserved in RPMI 1640 medium, 20% fetal calf serum (FCS), and 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen until use.
Reagents and cells
The GSK-3 inhibitor AR-A014418 14 was obtained from Calbiochem (La Jolla, CA). Z-VAD-FMK (broad spectrum caspase inhibitor) was from BIOMOL Research Laboratories (Plymouth Meeting, PA). All other chemicals were obtained from Sigma (St Louis, MO). MEC1, a cell line developed from a patient with CLL 15 was a kind gift from Dr. Frederico Caligaris-Cappio and maintained in RPMI 1640 medium supplemented with 10% FCS, L-glutamine, and penicillin/streptomycin. Primary CLL B cells and human splenic B cells were sorted by CD19 ϩ (Miltenyi Biotec, Auburn, CA) and were then cultured in serum-free AIM-V (Gibco BRL) and RPMI (BIOMOL Research Laboratories) supplemented with 10% FCS, respectively. Cells were maintained at 37°C in an atmosphere containing 95% air/5% CO 2 (v/v).
Immunoblot analysis and antibodies
For immunoblots, cells were lysed as described previously. 12 Nuclear/ cytosolic fractionation was done by the Dignam method. 16 Protein sample concentration was quantified and equal amount (50 g of whole, nuclear, or cytosolic protein extract) of protein was loaded in each well of SDSpolyacrylamide gel. Cell or tissue extracts were separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE), transferred to polyvinylidene diflouride membrane (PVDF), and probed as indicated in the figure legends. Antibodies for immunoblot analysis were obtained from the following suppliers: GSK-3␤, Bcl-2, XIAP, phospho-p65 (Ser536), poly-(ADP-ribose) polymerase (PARP), and ORC2 from BD Pharmingen (San Diego, CA); NFB p65 from Santa Cruz Biotechnology (Santa Cruz, CA); Cu/Zn superoxide dismutase (SOD) from Stressgen (Victoria, BC, Canada); and ␤-actin from Novus (Littleton, CO). Bound antibodies were detected as described previously. 12 Western blot band intensities were quantified using Image J software (http://rsb.info.nih.gov/ij/; National Institutes of Health, Bethesda, MD).
Immunocytochemical staining
CLL B cells and normal human B cells on glass coverslips were subjected to immunofluorescence staining 17 to detect GSK-3␤ expression with the same primary antibody (diluted 1:1000) used for immunoblotting. After a wash in phosphate-buffered saline, cells were incubated with goat anti-mouse-tetramethylrhodamine isothiocyanate (TRITC) secondary antibody (Invitrogen, Carlsbad, CA). Nuclei were counterstained with Hoechst 33342. Images were collected using the AxioVision 4.0 program on a Zeiss Axiovert 200 confocal microscope (Carl Zeiss Inc, Hallbergnoos, Germany) equipped with 100ϫ/1.4 oil DiC objective. SlowFade mounting medium (Invitrogen) was used, and a Zeiss AxioCam HRC camera (Zeiss).
Apoptosis assay
Primary CLL B cells (1 ϫ 10 6 cells) were treated with either vehicle (DMSO) or AR-A014418. After the treatment, cells were rinsed with 1 ϫ PBS and analyzed for apoptosis/cell death levels by a fluorescein isothiocyanate (FITC)-labeled Annexin-V/propidium iodide assay. These cells were directly analyzed in a FACScan (BD Biosciences, San Jose, CA) with a sample size of at least 10 000 cells gated based on forward and side scatter. Storing and processing of data were accomplished using FACScan software as described previously. 18
Reverse transcription-polymerase chain reaction
Expression of mRNA of XIAP and Bcl-2 was determined by reverse transcription-polymerase chain reaction (RT-PCR). cDNA was generated from 2 g of total RNA by reverse transcription using a reverse transcription system kit (Promega, Madison, WI). To quantify the expression in each cDNA sample, the target was amplified by PCR in parallel with an internal control, ␤-2-microglobulin. Primer pairs that detect XIAP, Bcl-2, and ␤-2-microglobulin were used as described previously. 12, 19 Amplification was performed by using a thermal cycling program with various numbers of cycles for XIAP (25 cycles) and Bcl-2 (22 cycles) in which each cycle consisted of 94°C for 45 seconds, 52°C (XIAP) or 58°C (Bcl-2) for 45 seconds, and 72°C for 1 minute. Amplification for ␤-2-microglobulin (22 cycles) was performed following a cycling program, in which each cycle consisted of 94°C for 45 seconds, 55°C for 45 seconds, and 72°C for 1 minute. All PCR products were subjected to electrophoresis through a native 8% polyacrylamide gel and were visualized by staining with ethidium bromide.
Chromatin immunoprecipitation assay
MEC1 cells were treated with 25 mol/L of AR-A014418 or control DMSO. The broad-spectrum caspase inhibitor N-benzyloxycarbonyl-ValAla-Asp-fluoromethyl ketone (Z-VAD-FMK) was used in some experiments. At 12 hours after treatment, cells were cross-linked with formaldehyde for 15 minutes at 25°C, harvested in SDS lysis buffer (Upstate Biotechnology, Lake Placid, NY), and sheared to fragment DNA (500-1000 base pairs [bp]). Samples were then immunoprecipitated using an agaroseconjugated p65, dimethyl-histone H4 (Lys20), dimethyl-histone H3 (Lys9), trimethyl-histone H3 (Lys27) antibody, or mouse control IgG at 4°C overnight. Antibodies for chromatin immunoprecipitation (ChIP) analysis were obtained from the following suppliers: dimethyl-H3-K9, trimethyl-H3-K27, and dimethyl-H4-K20 from Upstate Biotechnology (Lake Placid, NY); NFB p65 from Santa Cruz Biotechnology. After immunoprecipitation, samples were washed and eluted using the Chromatin Immunoprecipitation Kit (Upstate Biotechnology) according to the manufacturer's instructions. Cross-links were removed at 65°C for 6 hours, and immunoprecipitated DNA was purified using phenol/chloroform extraction and ethanol precipitation. Two hundred twenty base pairs of the Bcl-2 promoter and 250 bp of the XIAP promoter were detected in immunoprecipitated samples by PCR. PCR products were separated on a 2% agarose gel and visualized under UV light after staining with ethidium bromide.
Statistical analysis
Data were analyzed using Prism software (GraphPad Software, Inc., San Diego, CA). To evaluate the statistical significance of differences between group means, a one-way analysis of variance with a post-test was carried out, and P values less than .05 were considered statistically significant.
Results
GSK-3␤ was accumulated in the nucleus of CLL B cells
CLL B cell survival relies on different mechanisms to circumvent apoptosis, including the constitutive activation of NFB. 5, 6 Consistent with the hypothesis that NFB is constitutively active in CLL B cells, we found nuclear accumulation of p65 (RelA) in CLL B cells in 7 patients with CLL, whereas p65 was not detected in the nucleus of normal human B cells ( Figure  1A-B) . Because phosphorylation of the NFB subunit p65 is associated with the transactivation potential of NFB 20 , we also assessed phosphorylation of p65 in CLL B cells ( Figure 1B) . We have shown that GSK-3␤ regulates NFB activity at a point downstream of the activation of the IKK complex 12 and aberrantly accumulates in nuclei of pancreatic cancer cells, 21 implying a role for nuclear GSK-3␤ in the regulation of NFB transcriptional activity in pancreatic cancer cells. In light of these results and knowing that NFB is activated in CLL B cells, 5, 6 we sought to determine whether GSK-3␤ accumulates in the nuclei of CLL cells, where it might contribute to NFB transcriptional activity. Using nuclear/cytosolic fractionation, we found nuclear localization of GSK-3␤ in malignant B cells obtained from 7 patients with CLL, but only traces of this protein were detected in the nuclear fraction of normal human B cells ( Figure 1A-B) . Using immunofluorescence staining, we detected nuclear accumulation of GSK-3␤ in CLL B cells, whereas only cytoplasmic expression of GSK-3␤ was observed in normal human B cells ( Figure 1C) . Thus, nuclear accumulation of NFB p65 and GSK-3␤ seems to be a feature of CLL B cells.
Pharmacologic inhibition of GSK-3 induced apoptosis in CLL B cells
Using human malignant B cells from patients with CLL, we tested ex vivo the effect of 3 chemically distinct small-molecule inhibitors of GSK-3: AR-A014418 (ATP-competitive), 14 SB216763 (ATP-competitive, arylindolemaleimide), 22 and TDZD8 (non-ATP-competitive, thiadiazolidinone derivative). 23 AR-A014418 inhibits GSK-3 kinase activity (IC 50 ϭ 104 nM) and does not significantly inhibit CDK2 or CDK5 (IC 50 Ͼ 100 mol/L) or 26 other kinases demonstrating the high specificity for GSK-3. 14 SB216763 inhibits GSK-3 with an IC 50 value of 100 nM with no significant inhibition of 24 other protein kinases. 22 TDZD8, a potent inhibitor of GSK-3 (IC 50 ϭ 2 mol/L), did not inhibit protein kinases A or C, CK-2, or CDK1/cyclin B kinases at Ͼ 100 mol/L. 23, 24 Using Western immunoblotting, we estimated the level of GSK-3 inhibition by detection of the level of phosphorylated glycogen synthase, a primary GSK-3 substrate. We found that all 3 distinct GSK-3 inhibitors can decrease the level of phospho-glycogen synthase and induce apoptosis (as measured by PARP cleavage) in B cells obtained from patients with CLL ( Figure 2A) . Likewise, treatment of MEC1 CLL cells with different concentrations of AR-A014418 resulted in a dose-dependent inhibition of GSK-3 activity, as measured by the levels of phosphorylated glycogen synthase ( Figure 2B ).
Using Annexin-V staining and subsequent flow cytometry, we detected apoptotic cells as an Annexin-V ϩ population within DMSO or AR-A014418-treated MEC1 CLL B-cell line and malignant B cells cultured ex vivo from each of 10 patients with CLL ( Figure 2C-D) . After completion of these experiments, we summarized the data for 10 patients with CLL and represented it as a mean value ( Figure 2D ). Although the mean number of apoptotic cells was 26 Ϯ 9% in DMSO-treated malignant B cells, the apoptotic cell fraction in the AR-A014418-treated malignant B cells was significantly higher; the mean number of apoptotic cells reached 53 Ϯ 7% (AR-A014418, 10 mol/L) and 72 Ϯ 5% (AR-A014418, 25 mol/L) after 48 hours of exposure ( Figure  2D ; P Ͻ .001). We found that inhibition of GSK-3 in the MEC1 CLL B-cell line consistently resulted in a dose-dependent increase in the number of apoptotic cells ( Figure 2C ). Next, we treated malignant B cells from 11 patients with CLL with 25mol/L AR-A014418 or diluent (DMSO control) for 24, 48, or 72 hours. Because malignant B cells are susceptible to apoptosis in culture, we detected some PARP cleavage in DMSO-treated CLL B cells (Figure 3) . However, more pronounced or complete PARP cleavage was observed in AR-A014418-treated versus DMSO-treated malignant B cells in all 11 patients with CLL ( Figure 3 ). Taken together, these results suggest that inhibition of GSK-3 induces apoptosis in CLL B cells.
Pharmacologic inhibition of GSK-3 decreased NFB-mediated expression of antiapoptotic molecules in CLL B cells
We have shown that GSK-3␤ plays a critical role in NFBmediated survival of pancreatic cancer cells. 12 Because CLL B-cell survival also relies on constitutively active NFB, we have investigated whether inhibition of GSK-3 affects NFBmediated expression of antiapoptotic molecules in CLL B cells. Immunoblot analysis revealed a significant decrease in the expression of the antiapoptotic proteins XIAP and Bcl-2 in AR-A014418-treated CLL B cells from the 11 patients with CLL ( Figure 3 ). Using RT-PCR, we found that inhibition of GSK-3 in malignant B cells from patients with CLL resulted in decreased expression of NFB target genes XIAP and Bcl-2 ( Figure 4A ). To determine whether XIAP and Bcl-2 down-regulation was a cause or a consequence of caspase activation and apoptotic cell death, we treated CLL B cells with DMSO, AR-A014418, Z-VAD-FMK (irreversible, broad spectrum caspase inhibitor), or a combination of AR-A014418 and Z-VAD-FMK. We found that although Z-VAD-FMK could rescue the apoptotic effect of GSK-3 inhibition by AR-A014418 in CLL B cells, Z-VAD-FMK did not inhibit the decrease in XIAP and Bcl-2 mRNA or protein levels in AR-A014418-treated CLL B cells ( Figure 4B-C) . Thus, decreased expression of NFB target genes XIAP and Bcl-2 in AR-A014418-treated CLL B cells occurs before the activation of caspases. Taken together, these results suggest that GSK-3 affects the expression of the NFB target genes XIAP and Bcl-2 in CLL B cells, resulting in decreased cell survival.
GSK-3 regulated the binding of NFB p65 to its target gene promoters in CLL cells
Although the role of nuclear GSK-3␤ is unclear, some reports have suggested that it is required to modulate the activity of several nuclear proteins, including transcription factors. 25, 26 We have found both GSK-3␤ and active NFB p65 in the nuclei of malignant B cells obtained from 6 patients with CLL ( Figure 1A ). Our results, as shown in Figures 2-4 , suggest that GSK-3 can regulate the expression of NFB target genes, known to participate in CLL B-cell survival. These observations prompted us to further explore the relationship between aberrant GSK-3␤ nuclear accumulation and NFB transcriptional activity in CLL B cells.
Treatment of CLL B cells with AR-A014418 for 12 hours resulted in a marked reduction in the expression of the NFB target genes XIAP and Bcl-2 (Figure 4) , suggesting a loss of NFB transcriptional activity. To further investigate the role of GSK-3 in the regulation of NFB activity, we determined whether NFB p65 levels changed in the nuclei of MEC1 cells after inhibition of GSK-3. Consistent with the idea that GSK-3␤ positively modifies only NFB transcriptional activity downstream to the IKK complex, 12 we found that nuclear levels of p65 were not significantly changed in the nucleus of AR-A014418-treated MEC1 cells, but GSK-3␤ protein levels were diminished substantially ( Figure 5A ). These results indicate that the inhibition of GSK-3 does not affect the nuclear accumulation of p65 NFB but might alter its ability to regulate target gene promoters in CLL B cells. To further evaluate this possibility, we analyzed whether p65 could bind to the promoters of its target genes after GSK-3 inhibition using ChIP in MEC1 cells and malignant B cells obtained from 5 patients with CLL. In fact, p65 was bound at both the Bcl-2 and XIAP promoters in DMSO-treated MEC1 cells ( Figure 5B-C) and CLL B cells ( Figure 5D ) but was significantly diminished in cells treated with AR-A014418 (Figure 5B-D; compare DMSO with AR-A014418 [ARA]). It is noteworthy that Z-VAD-FMK treatment of MEC1 B cells did not affect the binding of p65 to its target gene promoters, and addition of Z-VAD-FMK to AR-A014418-treated MEC1 cells still resulted in an inability of p65 to bind to the promoters of XIAP and Bcl-2 ( Figure 5C ). Taken together, these data suggest that GSK-3 regulates the binding of p65 to the promoters of these 2 target genes in CLL B cells. Moreover, the inability of Z-VAD-FMK treatment to reverse the effects of AR-A014418 on p65 binding at the XIAP and Bcl-2 promoters further indicates that the effects of GSK-3 inhibition on NFB-mediated gene transcription occur before the onset of apoptosis.
Inhibition of GSK-3 results in epigenetic silencing of the XIAP and Bcl-2 promoters in CLL B cells
Opening of chromatin to allow transcription factors to gain access to gene promoters and regulate gene transcription is one of the major functions of histone modifications (ie, phosphorylation, acetylation, and methylation). 27 It has been suggested that GSK-3␤ does not affect histone acetylation, a hallmark of open chromatin structure and gene activation, at promoters of NFB target genes. 28 To evaluate the possibility that GSK-3 inhibition alters the ability of NFB to regulate its target genes through transcriptional repression, we used ChIP to assess histone methylation at the NFB target gene promoters in MEC1 cells and malignant B cells from 5 patients with CLL who were treated with diluent (DMSO) or 25 mol/L AR-A014418 for 12 hours. Methylation of H3-K9 (histone H3, lysine 9), H3-K27 (histone H3, lysine 27), and H4-K20 (histone H4, lysine 20) are known features of repressive chromatin status and epigenetic gene silencing. 29, 30 We found a significant increase in methylation of H3-K9, H3-K27, and H4-K20 bound to the promoters of the NFB target genes Bcl-2 and XIAP in AR-A014418-treated MEC1 cells and malignant B cells from patients with CLL ( Figure 6A-B) . We consistently found increased methylation of H3-K9, H3-K27, and H4-K20 at the promoters of the NFB target genes Bcl-2 and XIAP in CLL B cells treated with a combination of AR-A014418 and caspase inhibitor Z-VAD-FMK ( Figure 6C ), indicating that the chromatin remodeling was taking place in the absence of caspase activation. These results suggest that GSK-3 contributes to the maintenance of active chromatin at NFB target gene promoters, allowing p65 binding and transcriptional activation.
Discussion
Constitutively active NFB is known as an important factor of cancer cell survival in human tumorigenesis. 31 Human CLL B cells exhibit high constitutive levels of NFB activity, and survival of CLL B cells mainly relies on NFB-mediated expression of antiapoptotic molecules. 5, 6 It has been suggested that GSK-3␤ is an important regulator of NFB transcriptional activity, 11 and we have previously shown that inactivation of GSK-3 or genetic depletion of GSK-3␤ by RNA interference suppresses basal NFB transcriptional activity, leading to decreased pancreatic cancer cell proliferation and survival. 12 Recent studies have shown that inhibition of GSK-3 also decreases survival of colon and prostate cancer cells. [32] [33] [34] Most recently, it has been demonstrated that GSK-3␤ positively regulates NFB-mediated drug resistance in acute myeloid leukemia (AML), suggesting GSK-3␤ as a critical therapeutic target in resistant blasts of AML. 35 Overall, these findings also suggest a more global role for GSK-3␤ in human malignancy.
However, we are unaware of any previous report that assessed the role of GSK-3 and the effect of its inhibition on NFB-mediated cell survival in CLL. In the present study, we found aberrant nuclear accumulation of GSK-3␤ in malignant B cells obtained from patients with CLL. Further, we demonstrate that pharmacologic inhibition of GSK-3 leads to depletion of its nuclear pool, suppression of NFB transcriptional activity, decreased expression of antiapoptotic proteins (XIAP, Bcl-2), and enhanced apoptosis in CLL cells. Moreover, we provide evidence that inhibition of GSK-3 affects histone modification, resulting in transcriptional repression of NFB target genes (XIAP, Bcl-2) involved in CLL cell survival. Taken together, our results suggest GSK-3 as a novel potential therapeutic target in the treatment of CLL.
GSK-3␤ protein overexpression was recently reported in human pancreatic, 21 ovarian, 36 and colon 32 carcinomas. From a physiological perspective, GSK-3␤ is expressed in the cytoplasm of normal human cells, including normal B cells. Although GSK-3␤ contains no identifiable nuclear localization or nuclear export signal sequences, it has been suggested to shuttle from the cytoplasm to the nucleus, where it is thought to participate in the regulation of gene transcription through the phosphorylation of transcription factors. 25, 26 We found nuclear accumulation of GSK-3␤ in pancreatic cancer cell lines and in most poorly differentiated human pancreatic adenocarcinomas. 21 In the present study, we demonstrate aberrant nuclear accumulation of GSK-3␤ in human CLL B cells. Similar to our finding in pancreatic cancer, 21 inhibition of GSK-3 leads to depletion of its nuclear pool in CLL B cells, whereas nuclear level of NFB p65 remains unchanged. These results suggest that GSK-3␤ does not regulate nuclear accumulation of NFB but might be required for NFB transcriptional activity in human CLL B cells. ) were immunoprecipitated with dimethyl-H3-K9, trimethyl-H3-K27, and dimethyl-H4-K20 antibodies. Immunoprecipitated chromatin was analyzed by PCR for the methylation of H3-K9, H3-K27, and H4-K20 at the XIAP and Bcl-2 promoters. PCR analysis on input chromatin (first 2 lanes) confirmed that equal chromatin amounts were used for ChIP. (C) Binding of NFB p65 to the promoters of its target genes XIAP, and Bcl-2 was assayed in malignant B cells from a CLL patient treated with 25 mol/L AR-A014418 (ARA) or 50 mol/L Z-VAD-FMK (ZVAD) or AR-A014418 ϩ Z-VAD-FMK for 12 hours by ChIP. Immunoprecipitated chromatin was also analyzed for the methylation of H3-K9, H3-K27, and H4-K20 at the XIAP and Bcl-2 promoters as described in (panels A and B) .
